Evidence map›Paper›PMID 25794458›Full record

Observational studyEuropean urology2015

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.

Axel Gerdtsson, Jessica B Poon, Daniel L Thorek, Lorelei A Mucci, Michael J Evans, Peter Scardino, Per-Anders Abrahamsson, Peter Nilsson, Jonas Manjer, Anders Bjartell and 5 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in European urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Birth weight and birth length affect future fracture risk differently in men and women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Axel GerdtssonDepartment of Clinical Sciences (Urology), Lund University, Skåne University Hospital, Malmö, Sweden; Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
Jessica B PoonDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Daniel L ThorekDivision of Nuclear Medicine, Department of Radiology and Radiological Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Peter ScardinoDepartment of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Per-Anders AbrahamssonDepartment of Clinical Sciences (Urology), Lund University, Skåne University Hospital, Malmö, Sweden.
Peter NilssonDepartment of Clinical Sciences (Medicine), Lund University, Skåne University Hospital, Malmö, Sweden.
Jonas ManjerDepartment of Clinical Sciences (Surgery), Lund University, Skåne University Hospital, Malmö, Sweden.
Anders BjartellDepartment of Clinical Sciences (Urology), Lund University, Skåne University Hospital, Malmö, Sweden.
Johan MalmDepartment of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
Andrew VickersDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Stephen J FreedlandSurgery Section, Durham VA Medical Center, Durham, NC, USA; Department of Surgery (Urology), Cedars Sinai Medical Center, Los Angeles, CA, USA.
Hans LiljaDepartment of Clinical Sciences (Medicine), Lund University, Skåne University Hospital, Malmö, Sweden; Departments of Laboratory Medicine and Medicine (GU-Oncology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Institute of Biomedical Technology, University of Tampere, Tampere, Finland; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
David UlmertDepartment of Clinical Sciences (Urology), Lund University, Skåne University Hospital, Malmö, Sweden; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: ulmerth@mskcc.org.
Lund University · SEMemorial Sloan Kettering Cancer Center · USSkåne University Hospital · SEUniversity of California, San Francisco · USCedars-Sinai Medical Center · USHarvard University · USJohns Hopkins Medicine · USTampere University of Applied Sciences · FI

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PETR01CA176671 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI EVANS, MICHAEL JOHN, LEWIS, JASON S. · 2013 to 2017
$3.1M
Prospective validation of a multi-marker prostate cancer prediction modelR01CA160816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOORJIAN, STEPHEN, COOPERBERG, MATTHEW R · 2012 to 2015
$1.9M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
Long-term prediction of prostate cancer death from kallikreins measured in bloodR33CA127768 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LILJA, HANS GÖSTA · 2010 to 2011
$692k
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrinK99CA172695 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI EVANS, MICHAEL JOHN · 2013 to 2013
$91k
NCI NIH HHS K24 CA160653NCI NIH HHS K99 CA172695NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA160816NCI NIH HHS R01 CA176671NCI NIH HHS R33 CA127768
6 · The paper itself

Abstract

backgroundPrevious studies of prostate cancer (PCa) risk and anthropometrics (ie, body measurements) were based on single measurements or obtained over limited time spans.

objectiveTo study the association between anthropometrics measured at multiple time points in life and their relation to later diagnosis, metastasis, or death from PCa. DESIGN, SETTING, AND

participantsThis case-control study includes 27 167 Swedish men enrolled in two population-based projects from 1974 to 1996. PCa diagnosis up to December 31, 2006, disease information, gestation time, and anthropometrics at birth, military conscript testing, and adulthood were collected. A total of 1355 PCa cases were matched with 5271 controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate conditional logistic regression was used to determine whether clinical diagnosis, metastasis, or PCa death was associated with low birth weight (weight <2500 g); with small size for gestational age; or with weight, length, or body mass index (BMI) at birth, adolescence (aged 16-22 yr), or early middle age (aged 44-50 yr). RESULTS AND LIMITATIONS: Apart from weight at adolescence, which was associated with an increased risk of PCa diagnosis (odds ratio [OR] per 5 kg: 1.05; 95% confidence interval [CI], 1.01-1.09; p=0.026), preadulthood measurements were not associated with any PCa end point. Adulthood parameters were not associated with diagnosis. In contrast, weight and BMI at early middle age were significantly associated with metastasis (OR per 5 kg: 1.13; 95% CI, 1.06-1.20; p<0.0001, and OR: 1.09; 95% CI, 1.05-1.14; p<0.0001) and death (OR per 5 kg: 1.11 (95% CI, 1.03-1.19; p=0.005, and OR: 1.08; 95% CI, 1.03-1.13; p=0.003), respectively. It remains unclear whether these results apply to men of nonwhite origin, to populations with active PCa screening programs, or to countries without socialized health care.

conclusionsThe analyses of these large data sets demonstrate that significant effects of body characteristics (with links to metabolic syndrome) measured at early middle age are associated with PCa disease severity, metastatic progression, and outcome. Conversely, measurements at birth and adolescence are not associated with PCa prevalence or outcome. PATIENT SUMMARY: Increased weight and body mass index in adults is associated with a higher risk of prostate cancer metastasis and death.

Indexed as

Body Weights and MeasuresAdolescentAdultAgedAge FactorsCase-Control StudiesHumansInfant, NewbornMaleMiddle AgedNeoplasm MetastasisProstatic NeoplasmsRetrospective StudiesYoung AdultExposure windowsLong-term risk predictionsMetabolic syndrome–associated anthropometricsProstate cancerRisk factors

Identifiers

PMID25794458
PMCPMC4573834
OpenAlexW2004151015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.